Literature DB >> 26351496

Detection of Multidrug Resistant (MDR) and Extremely Drug Resistant (XDR) P. Aeruginosa Isolated from Patients in Tehran, Iran.

Horieh Saderi1, Parviz Owlia1.   

Abstract

BACKGROUND: This study was done to detect multidrug resistant (MDR) and extremely drug resistant (XDR) of Pseudomonas aeruginosa among strains isolated from patients in Tehran, Iran, due to importance of these phenotypes in treatment of human infections.
METHODS: Eighty eight P. aeruginosa were isolated from patients in Tehran, Iran, and identified by routine methods and PCR for oprL gene. Their antimicrobial susceptibility to 16 antimicrobial agents from 7 antimicrobial categories (aminoglycosides, carbapenems, cephalosporins, fluoroquinolones, penicillins/ß-lactamase inhibitors, monobactams, polymyxins) were determined by disk diffusion method, according to recommendation of Clinical and Laboratory Standards Institute. Characterization of P. aeruginosa isolates as MDR and XDR was done according to standardized international terminology presented by European Centre for Disease Prevention and Control as well as the Centers for Disease Control and Prevention in 2011. MDR was defined as acquired non-susceptibility to at least one agent in ≥3 antimicrobial categories and XDR was defined as non-susceptibility to at least one agent in ≥6 antimicrobial categories.
RESULTS: The rates of susceptibility to antimicrobials were as follows: gentamicin 27.3%, tobramycin 54.5%, amikacin 56.8%, netilmicin 36.4%, imipenem 55.7%, meropenem 55.7%, doripenem 60.2%, ceftazidime 63.6%, cefepime 56.8%, ciprofloxacin 59.1%, levofloxacin 60.2%, ticarcillin-clavulanic acid 37.5%, piperacillin-tazobactam 63.6%, aztreonam 43.2%, colistin 90.9%, polymyxin 95.5%. Altogether, 48 (54.5%) and 29 (33%) isolates were characterized as MDR and XDR, respectively. DISCUSSION: The high frequency of antibiotic resistance in clinical isolates of P. aeruginosa in Iran makes epidemiological surveillance of susceptibility of this bacterium more essential for the best selection of empirical antibiotics.

Entities:  

Keywords:  Bacterial; Drug Resistance; Multiple; Pseudomonas aeruginosa

Year:  2015        PMID: 26351496      PMCID: PMC4539747     

Source DB:  PubMed          Journal:  Iran J Pathol        ISSN: 1735-5303


  19 in total

1.  Characterization of Pseudomonas aeruginosa strains isolated from burned patients hospitalized in a major burn center in Tehran, Iran.

Authors:  Reza Ranjbar; Parviz Owlia; Horie Saderi; Sadegh Mansouri; Nematollah Jonaidi-Jafari; Morteza Izadi; Shohreh Farshad; Mohammad Arjomandzadegan
Journal:  Acta Med Iran       Date:  2011

Review 2.  Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.

Authors:  Robert A Bonomo; Dora Szabo
Journal:  Clin Infect Dis       Date:  2006-09-01       Impact factor: 9.079

3.  Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.

Authors:  Ching-Lan Lu; Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jene Teng; John D Turnidge; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

Review 4.  Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.

Authors:  Marilee D Obritsch; Douglas N Fish; Robert MacLaren; Rose Jung
Journal:  Pharmacotherapy       Date:  2005-10       Impact factor: 4.705

5.  Direct detection and identification of Pseudomonas aeruginosa in clinical samples such as skin biopsy specimens and expectorations by multiplex PCR based on two outer membrane lipoprotein genes, oprI and oprL.

Authors:  D De Vos; A Lim; J P Pirnay; M Struelens; C Vandenvelde; L Duinslaeger; A Vanderkelen; P Cornelis
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

6.  Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin.

Authors:  P D Lister; V M Gardner; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

7.  Prevalence of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in an Italian hospital.

Authors:  M A De Francesco; G Ravizzola; L Peroni; C Bonfanti; N Manca
Journal:  J Infect Public Health       Date:  2013-02-12       Impact factor: 3.718

8.  Clinical characteristics and risk factors of colistin-induced nephrotoxicity.

Authors:  Jieun Kim; Kyoung-Ho Lee; Sunmi Yoo; Hyunjoo Pai
Journal:  Int J Antimicrob Agents       Date:  2009-09-01       Impact factor: 5.283

Review 9.  Pseudomonas aeruginosa - a phenomenon of bacterial resistance.

Authors:  Tanya Strateva; Daniel Yordanov
Journal:  J Med Microbiol       Date:  2009-06-15       Impact factor: 2.472

10.  Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition.

Authors:  Eva Morales; Francesc Cots; Maria Sala; Mercè Comas; Francesc Belvis; Marta Riu; Margarita Salvadó; Santiago Grau; Juan P Horcajada; Maria Milagro Montero; Xavier Castells
Journal:  BMC Health Serv Res       Date:  2012-05-23       Impact factor: 2.655

View more
  16 in total

Review 1.  Virulence attenuating combination therapy: a potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients.

Authors:  Elana Shaw; William M Wuest
Journal:  RSC Med Chem       Date:  2020-02-19

Review 2.  Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.

Authors:  Yu-Xuan Ma; Chen-Yu Wang; Yuan-Yuan Li; Jing Li; Qian-Qian Wan; Ji-Hua Chen; Franklin R Tay; Li-Na Niu
Journal:  Adv Sci (Weinh)       Date:  2019-12-05       Impact factor: 16.806

3.  Systematic review and meta-analysis of imipenem-resistant Pseudomonas aeruginosa prevalence in Iran.

Authors:  Hamid Vaez; Amin Salehi-Abargouei; Farzad Khademi
Journal:  Germs       Date:  2017-06-01

4.  Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers.

Authors:  James J Howard; Carolyn R Sturge; Dina A Moustafa; Seth M Daly; Kimberly R Marshall-Batty; Christina F Felder; Danniel Zamora; Marium Yabe-Gill; Maria Labandeira-Rey; Stacey M Bailey; Michael Wong; Joanna B Goldberg; Bruce L Geller; David E Greenberg
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 5.  Prevalence of Clinically Isolated Metallo-beta-lactamase-producing Pseudomonas aeruginosa, Coding Genes, and Possible Risk Factors in Iran.

Authors:  Abdolmajid Ghasemian; Kobra Salimian Rizi; Hassan Rajabi Vardanjani; Farshad Nojoomi
Journal:  Iran J Pathol       Date:  2018

6.  Multidrug Resistant Pseudomonas aeruginosa in Iran: A Systematic Review and Metaanalysis.

Authors:  Hamid Vaez; Amin Salehi-Abargouei; Zahra Rashki Ghalehnoo; Farzad Khademi
Journal:  J Glob Infect Dis       Date:  2018 Oct-Dec

7.  Molecular epidemiology of colistin-resistant Pseudomonas aeruginosa producing NDM-1 from hospitalized patients in Iran.

Authors:  Ahmad Farajzadeh Sheikh; Mojtaba Shahin; Leili Shokoohizadeh; Mehrdad Halaji; Fereshteh Shahcheraghi; Fahimeh Ghanbari
Journal:  Iran J Basic Med Sci       Date:  2019-01       Impact factor: 2.699

Review 8.  Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria.

Authors:  Emily M Eichenberger; Joshua T Thaden
Journal:  Antibiotics (Basel)       Date:  2019-04-06

9.  High Prevalence of Multi-Drug Resistance and Extended Spectrum Beta Lactamase Production in Non-Fermenting Gram-Negative Bacilli in Ethiopia.

Authors:  Adane Bitew
Journal:  Infect Dis (Auckl)       Date:  2019-11-05

10.  Prevalence of metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from diabetic foot infections in Iraq.

Authors:  M K Al-Khudhairy; M M M Al-Shammari
Journal:  New Microbes New Infect       Date:  2020-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.